STOCK TITAN

Cytokinetics (CYTK) Form 144: Proposed 6,756-Share Sale Disclosed

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Cytokinetics, Inc. (CYTK) Form 144 notice reports a proposed sale of 6,756 common shares through Morgan Stanley Smith Barney, with an aggregate market value of $238,689.48 based on the filing. The filing lists 119,657,156 shares outstanding and an approximate sale date of 09/02/2025. The shares to be sold were acquired as Restricted Stock Units on 01/03/2022 and payment is marked N/A. The filer also disclosed 10b5-1 sales by Edward Kaye of 3,636 shares on 06/05/2025 for $116,714.87. The document contains standard Rule 144 attestations and a signature block; no relationship to the issuer or additional context is provided in the filing.

Positive

  • None.

Negative

  • None.

Insights

TL;DR: Routine Rule 144 disclosure of a small planned insider sale, with prior 10b5-1 sales also disclosed.

The filing documents a proposed sale under Rule 144 of 6,756 common shares via Morgan Stanley Smith Barney, acquired as RSUs on 01/03/2022. It includes a prior 10b5-1 sale by Edward Kaye of 3,636 shares on 06/05/2025 for $116,714.87. This is a standard regulatory notification ensuring public disclosure of insider sales and planned sales; the filing contains the required attestations but does not provide additional material company information.

TL;DR: Disclosure is compliant and routine; the transactions disclosed are small relative to outstanding shares.

The notice shows the shares were RSUs granted by the issuer and that the seller relies on Rule 144 for the proposed sale dated 09/02/2025. The filing properly lists broker, quantity, and aggregate value and discloses recent 10b5-1 activity. There is no evidence in this document of material corporate developments or governance events beyond normal insider share disposition reporting.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the CYTK Form 144 disclose about the proposed sale?

The filing discloses a proposed sale of 6,756 common shares with an aggregate market value of $238,689.48, scheduled approximately for 09/02/2025.

How were the shares being sold by the CYTK filer acquired?

The shares were acquired as Restricted Stock Units on 01/03/2022 and the filing lists the acquisition amount as 6,756 shares.

Does the CYTK filing report any recent insider sales?

Yes. It reports 10b5-1 sales by Edward Kaye of 3,636 shares on 06/05/2025, generating gross proceeds of $116,714.87.

Which broker is listed for the proposed CYTK sale?

The broker listed is Morgan Stanley Smith Barney LLC, Executive Financial Services, 1 New York Plaza 8th Floor New York NY 10004.

How many CYTK shares are outstanding according to the filing?

The filing lists 119,657,156 shares outstanding.
Cytokinetics Inc

NASDAQ:CYTK

CYTK Rankings

CYTK Latest News

CYTK Latest SEC Filings

CYTK Stock Data

8.29B
120.00M
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO